title: Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
abstract: To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA).
  
  
  
  Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 µg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and non-surgical FTMH closure [month 6]).
  
  
  
  Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI], 1.1-3.7), VMA diameter of 1,500 µm or less (OR = 4.9; 95% CI, 2.0-12.4), phakic lens status (OR = 2.8; 95% CI, 1.5-5.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2-7.9) predicted VMA resolution. FTMHs with apical diameter of 250 µm or less were more likely to close than larger holes (58.3% vs. 24.6%; P = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls.
  
  
  
  Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:716-723.].
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Jackson
authors.forename: Carl D
authors.initials: CD
authors.lastname: Regillo
authors.forename: Aniz
authors.initials: A
authors.lastname: Girach
authors.forename: Pravin U
authors.initials: PU
authors.lastname: Dugel
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology*; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D011446:Prospective Studies; D012167:Retinal Perforations / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D000267:Tissue Adhesions / Q000188:drug therapy / Q000473:pathology; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects / Q000473:pathology*; D020255:Vitreous Detachment / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin